Publications & Posters
Scholary publications
Immuno-Oncology
SRK-181
March 2021
International Journal of Toxicology
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
Spinal Muscular Atrophy
Apitegromab
March 2021
2021 MDA Virtual Clinical & Scientific Conference
Apitegromab, a Novel High-Affinity Anti-proMyostatin Monoclonal Antibody for Treating Spinal Muscular Atrophy: Results of a Phase 2 Interim Analysis (Presentation)
Spinal Muscular Atrophy
Apitegromab
March 2021
2021 MDA Virtual Clinical & Scientific Conference
Apitegromab, a Novel High-Affinity Anti-Promyostatin Monoclonal Antibody for Treating Spinal Muscular Atrophy: Results of a Phase 2 Interim Analysis
Immuno-Oncology
SRK-181
January 2021
2021 TGFβ for Immuno-Oncology Drug Development Summit
Inhibition of TGFβ1 Activation with SRK-181 Overcomes Primary Resistance to Checkpoint Inhibition Therapy
Immuno-Oncology
SRK-181
November 2020
Society for Immunotherapy of Cancer's (SITC) Annual Meeting
DRAGON: Phase 1 trial of SRK-181, a latent TGFβ1 inhibitor, in combination with anti-PD-(L)1 inhibitors for patients with solid tumors unresponsive to anti-PD-(L)1 therapy alone
Spinal Muscular Atrophy
Apitegromab
September 2020
World Muscle Society
